|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,880.00 JPY | +6.77% |
|
+7.88% | +22.62% |
| 03-04 | Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc | FW |
| 02-26 | Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study | FW |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.62x | 1.66x | -0.93x | 1.95x | 9.56x | 12.73x | 1.4% | 34.11B | ||
| 37.27x | 5.41x | 5.58x | 7.1x | 24.31x | 29.51x | 0.82% | 47.36B | ||
| 25.71x | 3.12x | -1.25x | 3.47x | 16.4x | 20.21x | 1.03% | 11.73B | ||
| 20.44x | 3.33x | 49.74x | 3.54x | 13.2x | 15.94x | 0.88% | 10.11B | ||
| 89.72x | 6.95x | 7.81x | - | - | - | 1% | 8.76B | ||
| 18.7x | 3.12x | 3.1x | 3.2x | 11.87x | 14.29x | 3.59% | 8.16B | ||
| 16.33x | 1.39x | 0.42x | 2.11x | 7.97x | 10.68x | 3.24% | 7.18B | ||
| 35.11x | 6.07x | 0.5x | 3.82x | 17.36x | 18.19x | 0.13% | 6.84B | ||
| 9.41x | 1.52x | -1.9x | 2.05x | 5.55x | 6.67x | 4.52% | 6.46B | ||
| 39.79x | 5.38x | 1.16x | 4.34x | 19.66x | 27.42x | 0.21% | 4.42B | ||
| 35.33x | 8.32x | 2.29x | 6.81x | 25.06x | 27.95x | 1.11% | 4.08B | ||
| 20.81x | 3.32x | 0.28x | 3.48x | 16.72x | 20.34x | 2.35% | 3.95B | ||
| 13.45x | 0.69x | -0.03x | 2.12x | 8.97x | 11.43x | 1.57% | 3.81B | ||
| 15.64x | 3.62x | 0.85x | 3.69x | 13.2x | 14.47x | 2.56% | 2.91B | ||
| 19.55x | 5.37x | 0.54x | 6.24x | 17.81x | 18.94x | 3.07% | 2.53B | ||
| Average | 27.73x | 3.95x | 4.54x | 3.85x | 14.83x | 17.77x | 1.83% | 10.83B | |
| Weighted average by Cap. | 29.64x | 3.87x | 5.10x | 4.26x | 16.17x | 19.79x | 1.45% |
- Stock Market
- Equities
- 4578 Stock
- Sector Otsuka Holdings Co., Ltd.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















